One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Absci Corporation
ABSI · NMS · Healthcare · Biotechnology
Current price
$9.56
52-week range
$2.24 - $12.05
Market cap
$1.64B
Balance sheet
Healthy
-600.09x Concerning
Net cash $197.31M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Operating margin compressed from -1857.5% to -10741.5% over 3 years.
- Risk Return on equity was -57.7% last year — the company lost money on shareholders' equity.
What this company does
Absci Corporation
Absci is a company that is trying to create new medicines, specifically antibody therapies for diseases like inflammatory bowel disease, hair loss, and cancer. Their main money comes from partnerships and research with other companies, which is important because it helps fund their drug development efforts while sharing the risk. This approach means they don't solely rely on selling a product yet, as their drugs are still in the early stages of testing.
How the company got here
Absci Corporation was founded in 2011 with a vision to make drug discovery more efficient by integrating artificial intelligence (AI) with synthetic biology. The company's journey has involved evolving its technology platform, moving from a focus on protein production to a more comprehensive AI-driven drug creation process. A key turning point was its transition into a public company, completing a reorganization in October 2020 and subsequently listing on NASDAQ. This allowed Absci to raise capital to further develop its proprietary technologies and advance its pipeline of drug candidates. The company has also strategically partnered with major pharmaceutical and biotechnology firms, leveraging these collaborations to fund research and development while validating its platform's capabilities.
What it actually does
Absci is a biotechnology company that uses artificial intelligence (AI) and synthetic biology to discover and develop new medicines, specifically biologic drugs. Think of it like using a super-smart computer program that can design potential drug molecules much faster than traditional methods. These AI-designed drugs are then tested and refined in their labs. The company's main goal is to create 'better biologics for patients, faster,' meaning they aim to develop more effective and potentially easier-to-administer treatments for various diseases.
AI-Driven Drug Creation Platform
Absci's core business revolves around its Integrated Drug Creation™ Platform. This platform uses generative AI (AI that can create new data, like drug designs) and synthetic biology to design and optimize biologic drug candidates. The process involves a continuous cycle: data is used to train AI models, the AI creates potential drug designs, and then these designs are validated in their wet labs. This iterative approach allows Absci to rapidly design and test new drug molecules, aiming to create more effective treatments for challenging diseases. The company generates revenue through partnerships with other pharmaceutical and biotech companies, offering its platform for drug development and optimization, and earning milestone payments and royalties.
Internal Pipeline Programs
While Absci collaborates with other companies, it also develops its own drug candidates through its internal pipeline. These are potential new medicines that Absci is advancing on its own. For example, ABS-201 is an antibody designed to treat conditions like hair loss (androgenetic alopecia) and endometriosis. Another program, ABS-101, is being developed for inflammatory bowel disease. These internal programs represent Absci's direct efforts to bring its AI-designed therapeutics to market, with the aim of addressing significant unmet medical needs.
What management is betting on now
Absci's management is focused on advancing its internal drug pipeline, particularly its lead candidate ABS-201, and strengthening its AI-driven drug creation platform. They are investing heavily in clinical trials for their internal programs, aiming to demonstrate the efficacy and safety of their AI-designed therapeutics. Simultaneously, they continue to pursue strategic partnerships with larger pharmaceutical companies, which provide both funding and validation for their technology. The ultimate goal is to become a leader in AI-powered drug discovery, creating a more efficient and effective way to develop new medicines for patients.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-20.78M
FY2024 Q4
$-16.99M
FY2025 Q1
$-21.86M
FY2025 Q2
$-17.10M
FY2025 Q3
$-25.99M
FY2025 Q4
$-29.29M
FY2026 Q1
$-26.34M
FY2026 Q2
$-27.57M
Revenue
—
Net income
$-33.21M
Diluted EPS
-0.21
Operating cash flow
$-27.56M
Free cash flow
$-27.57M
Fetching…
Sources
Revenue
—
Net income
$-29.60M
Diluted EPS
-0.19
Operating cash flow
$-26.31M
Free cash flow
$-26.34M
Fetching…
Sources
Revenue
—
Net income
$-29.56M
Diluted EPS
-0.19
Operating cash flow
$-29.18M
Free cash flow
$-29.29M
Fetching…
Sources
Revenue
—
Net income
$-28.71M
Diluted EPS
-0.20
Operating cash flow
$-25.03M
Free cash flow
$-25.99M
Fetching…
Sources
Revenue
—
Net income
$-30.57M
Diluted EPS
-0.24
Operating cash flow
$-16.87M
Free cash flow
$-17.10M
Fetching…
Sources
Revenue
—
Net income
$-26.35M
Diluted EPS
-0.21
Operating cash flow
$-21.84M
Free cash flow
$-21.86M
Fetching…
Sources
Revenue
$665.00K
Net income
$-28.98M
Diluted EPS
-0.26
Operating cash flow
$-16.96M
Free cash flow
$-16.99M
Fetching…
Sources
Revenue
$1.70M
Net income
$-27.40M
Diluted EPS
-0.24
Operating cash flow
$-20.73M
Free cash flow
$-20.78M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $9.56
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $197.3M - more cash than debt. Interest coverage -600.1x.
Net debt
$-197.31M
Interest coverage
-600.09x
Absci Corporation's profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
ABSI
BASELINE
Absci Corporation
Total debt $3.83M Interest coverage -600.09x This is the baseline the peer rows are being compared against.
Total debt $108.00M Interest coverage -157.90x Neither company has much profit cushion over interest right now.
Total debt $66.64M Interest coverage -358.08x Neither company has much profit cushion over interest right now.
Total debt $30.66M Interest coverage -11.20x Neither company has much profit cushion over interest right now.
Total debt $72.59M Interest coverage -7.96x Neither company has much profit cushion over interest right now.
What you should know
The case for and against ABSI
0 Rewards
2 Risks
Rewards
Risks
-
Operating margin compressed from -1857.5% to -10741.5% over 3 years.
-
Return on equity was -57.7% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-14.16x
P/B
6.66x
P/S
1,051.01x
EV/EBITDA
-11.53x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
-10,741.5%
Net margin
0.0%
ROE
-57.7%
ROA
-34.1%
Health
Liquidity and balance-sheet strength
Debt / equity
0.02x
Current ratio
10.63x
Quick ratio
10.26x
Total debt
$3.83M
Total cash
$201.14M
Growth
How the business has been compounding
Revenue TTM
$4.53M
Revenue 5Y CAGR
-1.8%
EPS TTM
-0.79
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-108.08M
Free CF TTM
$-94.03M
FCF margin
-2,073.9%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—